Rutgers University Study of the Genetics of Blood Cancers
This study from Rutgers University is looking at the genes that might affect your risk of developing blood cancers like leukemia, lymphoma, and myeloma. There are no specific treatments or drugs being tested. Instead, researchers want to find new genetic differences and learn more about known ones related to these cancers. You can join if you are 18 or older, live in the US, and have internet access. The goal is to enroll 10,000 people. Success for this study means identifying genetic risk variants (changes in your genes that might increase your risk) associated with blood cancer within two years. The current recruitment status is unclear.
- Study design
- This is an observational study aiming to enroll 10,000 participants. It is an online research study.
- What's involved
- You will complete an online survey about your health and provide a saliva sample using a kit mailed to your home. This takes about 20 minutes.
- Compensation
- You may receive information about your genetic ancestry for free. Not stated in the trial record if there is other compensation.
- Follow-up
- Genetic risk variants associated with blood cancer will be measured at 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Rutgers University Study of the Genetics of Blood Cancers
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Tara Matise, PhD · PRINCIPAL_INVESTIGATOR · Rutgers University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Genetic risk variants associated with blood cancer2 years
Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype.